Abstract: The present invention relates to a drug-eluting nanoengineered medical implant/contact device. The device comprises a nanocomposite and a drug, wherein the nanocomposite comprises hydrophilic polymer domains, hydrophobic polymer domains, water pores, and boundary charged double layers; wherein when the drug is hydrophilic, at least 80% of the drug partitions in the boundary charged double layers formed at the boundary interface of the hydrophilic polymer domains and water pores, and when the drug is hydrophobic, at least 80% of the dmg partitions in the boundary charged double layers formed at the boundary interface of the hydrophobic polymer domains and water pores. The device is configured to sustain the release of the drug at high precision and long duration.

Abstract: The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.

Abstract: The present invention is directed to processes for preparing a silicone surfactant intercalated clay and a polymer-clay nanocomposite. The processes use silicone surfactants having a molecular weight in the range of 10,000 to 100,000 Dalton to achieve fully exfoliating clay structures. Using these macromolecular silicone surfactants, along with the engineered control of the processing pH and drying stress conditions, this invention provides simple and low-cost methods of making a fully-exfoliated polymer-clay nanocomposite.

Abstract: The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.

Abstract: The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.

Abstract: The present invention is directed to processes for preparing a silicone surfactant intercalated clay and a polymer-clay nanocomposite. The processes use silicone surfactants having a molecular weight in the range of 10,000 to 100,000 Dalton to achieve fully exfoliating clay structures. Using these macromolecular silicone surfactants, along with the engineered control of the processing pH and drying stress conditions, this invention provides simple and low-cost methods of making a fully-exfoliated polymer-clay nanocomposite.

Abstract: The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device can achieve both optical and medical functions. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject, wherein the drug partitions between the reservoir domain and the barrier layer, and the equilibrium drug solubility in the reservoir domain is at least five folds higher than that in the barrier layer.

Abstract: Thermally insulative xerogels and their preparation are described. To obtain these xerogels, an inorganic gel having hydroxyl moieties is reacted with a silicon-nitrogen compound which has a C.sub.1-6 hydrocarbon moiety on the silicon. Shrinkage of the gel during drying the gel is reduced and a more highly porous xerogel is obtained. The more highly porous xerogel has a low thermal conductivity which makes it a good thermal insulation.

Abstract: The present invention is directed to liquid cyrstalline polyesters which are soluble and have low melting points. Preferably the solubility in halogenated solvent is greater than 10 wt. % and the crystalline melting point is less than 125.degree. C. The polyesters are thermotropic and nematic, and preferably have a number average molecular weight from 1,000 to 25,000. The polyesters include a cyclohexane ring in the backbone and are more particularly main-chain thermotropic polyester which contain trans-1,4 cyclohexane dicarboxylate mesogens and flexible spacer groups. These compositions are useful in coating applications including floor coverings.